Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read More
Tag: NEJM
Nirsevimab shows promise for long-term RSV protection
The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
Read More
Hydroxychloroquine fails as postexposure prophylaxis for COVID-19
However, the trial did have limitations, researchers note
Read More
NEJM publishes second successful Epidiolex trial in LGS
The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.
Read More
GSK picks Kevin Sim to lead business development for pharma R&D
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
Read More
GW Pharma poised to file Epidiolex in the US
GW Pharmaceuticals is on the brink of filing its cannabis-derived therapy Epidiolex in the US as another late-stage study highlights the drug’s efficacy in treating Dravet Syndrome, a rare and severe type of epilepsy.
Read More
GSK’s Relvar Ellipta shows benefit for COPD patients
Further results from the UK Salford Lung Study have been unveiled showing that GlaxoSmithKline’s Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease.
Read More
60% response rate with Novartis’ rare blood cancer drug
A mid-stage trial assessing Novartis’ experimental rare blood cancer (midostaurin) has shown high response rates in patients with systemic mastocytosis.
Read More
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
- MHRA approves imlunestrant tosylate as new breast cancer treatment
- ACD440 granted orphan drug status in the EU
